Asymmetric Cell Division and Notch Signaling in Lung Cancer Stem Cells

肺癌干细胞中的不对称细胞分裂和Notch信号传导

基本信息

  • 批准号:
    7892613
  • 负责人:
  • 金额:
    $ 17.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-05-01 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death and is estimated to claim over 160,000 lives in the United States in 2008; thus, the study of lung tumor cell biology is critical for discovering novel targets to treat the disease. Recent evidence suggests that solid tumors comprise a small fraction of lung cancer stem cells that seed the tumor bulk and may be responsible for metastases and resistance to therapy. The mechanisms regulating how lung cancer stem cells undergo self-renewal and maintain tumor growth are unknown. In recent experiments, it was determined that a small fraction of lung cancer cells asymmetrically divide their template DNA, and that the process is abrogated by Notch pathway inhibitors. This finding has broad implications in normal and tumor cell homeostasis research. The central hypothesis of this proposal is that Notch signaling regulates the lung cancer stem cell pool by maintaining a dynamic balance between asymmetric and symmetric divisions. The objectives are to determine if asymmetrically dividing lung cancer cells are restricted to the cancer stem cell fraction and if Notch signaling regulates asymmetric cell division in lung cancer. The first specific aim to achieve these objectives is to study asymmetric cell division as a fundamental mechanism restricted to the lung CSC pool. The second aim is to investigate canonical Notch signaling as a regulator of asymmetric cell division and CSC self-renewal in lung cancer. This will be achieved by expression analysis of Notch pathway genes in asymmetrically dividing human lung cancer cells, and targeting of identified proteins for disruption of asymmetric cell division and alterations in self-renewal. The rationale of the proposed research is that, once it is known that self-renewal of the CSC pool is regulated by mechanisms that control asymmetric division, those pathways can later be targeted pharmacologically by new and innovative approaches in the treatment of lung cancer. PUBLIC HEALTH RELEVANCE: Cancer of the lung is the leading cause of cancer deaths in the United States. For several decades, there has been limited improvement in lung cancer survival that is attributed to early detection or targeted therapy, and the five-year survival rate hovers at a meager 15-20%. Studies aimed at unraveling the fundamental properties governing how lung tumors are maintained may lead to novel and more efficacious therapies.
描述(由申请人提供):肺癌是癌症死亡的主要原因,据估计,2008年美国有超过16万人死于肺癌;因此,对肺肿瘤细胞生物学的研究对于发现治疗该疾病的新靶点至关重要。最近的证据表明,实体瘤只占肺癌干细胞的一小部分,而这些干细胞是肿瘤的主要来源,可能是转移和对治疗产生耐药性的原因。调控肺癌干细胞自我更新和维持肿瘤生长的机制尚不清楚。在最近的实验中,确定了一小部分肺癌细胞不对称地分裂其模板DNA,并且该过程被Notch通路抑制剂所废除。这一发现对正常和肿瘤细胞稳态的研究具有广泛的意义。该建议的中心假设是Notch信号通过维持不对称和对称分裂之间的动态平衡来调节肺癌干细胞库。目的是确定肺癌细胞的不对称分裂是否仅限于癌症干细胞部分,以及Notch信号是否调节肺癌细胞的不对称分裂。实现这些目标的第一个具体目标是研究不对称细胞分裂作为一种仅限于肺CSC池的基本机制。第二个目的是研究典型Notch信号作为肺癌中不对称细胞分裂和CSC自我更新的调节因子。这将通过分析Notch通路基因在不对称分裂的人肺癌细胞中的表达,以及靶向鉴定的蛋白质来破坏不对称细胞分裂和改变自我更新来实现。提出的研究的基本原理是,一旦知道CSC库的自我更新是由控制不对称分裂的机制调节的,这些途径随后可以通过新的和创新的方法在治疗肺癌的药理学上靶向。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sharon R. Pine其他文献

BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V 600 E mutant 3 melanoma 4 5
BRAF 融合作为 BRAF V 600 E 突变体 3 黑色素瘤中对维莫非尼获得性耐药的新机制 4 5
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. Kulkarni;Husam Al;Srilatha Simhadri;K. Hirshfield;Suzie Chen;Sharon R. Pine;C. Jeyamohan;Levi Sokol;Siraj M. Ali;M. L. Teo;E. White;L. Rodriguez;J. Mehnert;S. Ganesan
  • 通讯作者:
    S. Ganesan
Lymphoproliferative clonal origin of AIDS-related non-Hodgkin's lymphoma
艾滋病相关非霍奇金淋巴瘤的淋巴增殖性克隆起源
  • DOI:
    10.1080/10428190601173109
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    2.6
  • 作者:
    H. Sabaawy;C. Sandoval;Qianxu Guo;Changhong Yin;A. Kulangara;Jooyun Lee;Gary Wormser;S. Jayabose;Sharon R. Pine
  • 通讯作者:
    Sharon R. Pine
Down syndrome Incidence and clinical implications of GATA1 mutations in newborns with
唐氏综合症新生儿 GATA1 突变的发病率和临床意义
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    C. Sandoval;Sharon R. Pine;Qianxu Guo;Changhong Yin;S. Jayabose;C. Druschel
  • 通讯作者:
    C. Druschel
Abstract 1957: Negative regulation of Sox9 by glycogen synthase kinase 3 beta phosphorylation and SCFFbw7-dependent ubiquitination in cancer
摘要 1957 年:癌症中糖原合酶激酶 3 β 磷酸化和 SCFFbw7 依赖性泛素化对 Sox9 的负调控
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xuehui Hong;Wenyu Liu;H. Inuzuka;Lianxin Liu;Sharon R. Pine
  • 通讯作者:
    Sharon R. Pine
GATA1 Mutations in Newborns with Down Syndrome.
患有唐氏综合症的新生儿中的 GATA1 突变。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    C. Sandoval;Sharon R. Pine;C. Druschel;S. Jayabose;Qianxu Guo;Changhong Yin
  • 通讯作者:
    Changhong Yin

Sharon R. Pine的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sharon R. Pine', 18)}}的其他基金

Discovery and therapeutic targeting of biological determinants of lung cancer health disparities
肺癌健康差异的生物决定因素的发现和治疗靶向
  • 批准号:
    10385769
  • 财政年份:
    2020
  • 资助金额:
    $ 17.96万
  • 项目类别:
Discovery and therapeutic targeting of biological determinants of lung cancer health disparities
肺癌健康差异的生物决定因素的发现和治疗靶向
  • 批准号:
    10158464
  • 财政年份:
    2020
  • 资助金额:
    $ 17.96万
  • 项目类别:
Discovery and therapeutic targeting of biological determinants of lung cancer health disparities
肺癌健康差异的生物决定因素的发现和治疗靶向
  • 批准号:
    10684394
  • 财政年份:
    2020
  • 资助金额:
    $ 17.96万
  • 项目类别:
Sox9 signaling in lung adenocarcinoma
肺腺癌中的 Sox9 信号传导
  • 批准号:
    8798984
  • 财政年份:
    2014
  • 资助金额:
    $ 17.96万
  • 项目类别:
Sox9 signaling in lung adenocarcinoma
肺腺癌中的 Sox9 信号传导
  • 批准号:
    9479728
  • 财政年份:
    2014
  • 资助金额:
    $ 17.96万
  • 项目类别:
Asymmetric Cell Division and Notch Signaling in Lung Cancer Stem Cells
肺癌干细胞中的不对称细胞分裂和Notch信号传导
  • 批准号:
    8250342
  • 财政年份:
    2011
  • 资助金额:
    $ 17.96万
  • 项目类别:
Asymmetric Cell Division and Notch Signaling in Lung Cancer Stem Cells
肺癌干细胞中的不对称细胞分裂和Notch信号传导
  • 批准号:
    8461918
  • 财政年份:
    2011
  • 资助金额:
    $ 17.96万
  • 项目类别:
Asymmetric Cell Division and Notch Signaling in Lung Cancer Stem Cells
肺癌干细胞中的不对称细胞分裂和Notch信号传导
  • 批准号:
    8700862
  • 财政年份:
    2011
  • 资助金额:
    $ 17.96万
  • 项目类别:

相似海外基金

Drug resistance and calcium signaling in cancer cell line
癌细胞系中的耐药性和钙信号传导
  • 批准号:
    20K16338
  • 财政年份:
    2020
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel target molecules involved in spontaneous bone metastasis of mouse breast cancer cell line.
鉴定参与小鼠乳腺癌细胞系自发骨转移的新靶分子。
  • 批准号:
    17K07159
  • 财政年份:
    2017
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Differential expression of cell adhesion molecule of CD133-positive / negative cells derived from oral cancer cell line and diagnostic treatment targeting it
口腔癌细胞系CD133阳性/阴性细胞细胞粘附分子的差异表达及针对其的诊断治疗
  • 批准号:
    17K17251
  • 财政年份:
    2017
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Two types of monoclonal antibodies generated by immunizing mice with MIA-PaCa-2 human pancreatic cancer cell line for diagnostic and therapeutic strategies for pancreatic cancer
用 MIA-PaCa-2 人胰腺癌细胞系免疫小鼠产生两种类型的单克隆抗体,用于胰腺癌的诊断和治疗策略
  • 批准号:
    16K10595
  • 财政年份:
    2016
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Metabolome analysis of invaded pancreatic cancer cell line, PANC-1, after irradiation
照射后侵袭性胰腺癌细胞系 PANC-1 的代谢组分析
  • 批准号:
    25461934
  • 财政年份:
    2013
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proteomics analysis of cancer stem cell and its microenvironment using FFPE tissue and cancer cell line
使用 FFPE 组织和癌细胞系对癌症干细胞及其微环境进行蛋白质组学分析
  • 批准号:
    25710013
  • 财政年份:
    2013
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Young Scientists (A)
Autophagy is involved in a clearance of anti-cancer agent doxorubicin in the multidrug resistant cancer cell line.
自噬参与多药耐药癌细胞系中抗癌药物阿霉素的清除。
  • 批准号:
    25670083
  • 财政年份:
    2013
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
An attempt to identify new antigens recognized by tumor-specific cytotoxic T lymphocytes using a HLA-modified ovarian cancer cell line as an artificial antigen presenting cell
尝试使用 HLA 修饰的卵巢癌细胞系作为人工抗原呈递细胞来鉴定肿瘤特异性细胞毒性 T 淋巴细胞识别的新抗原
  • 批准号:
    24659727
  • 财政年份:
    2012
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Studies on the epigenetic mechanism of arsenic carcinogenesis on human liver cancer cell line
砷致癌人肝癌细胞系的表观遗传机制研究
  • 批准号:
    23790680
  • 财政年份:
    2011
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Supramolecular Assembly of Amphiphilic Mesogenic Compounds InducingApoptosis in a Human Solid Cancer Cell Line
诱导人实体癌细胞系凋亡的两亲性介晶化合物的超分子组装
  • 批准号:
    23651229
  • 财政年份:
    2011
  • 资助金额:
    $ 17.96万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了